1. Home
  2. EVI vs SGMT Comparison

EVI vs SGMT Comparison

Compare EVI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVI Industries Inc.

EVI

EVI Industries Inc.

HOLD

Current Price

$15.34

Market Cap

204.6M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.35

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVI
SGMT
Founded
1959
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
169.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
EVI
SGMT
Price
$15.34
$7.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$35.00
$26.13
AVG Volume (30 Days)
83.9K
1.3M
Earning Date
05-15-2026
05-14-2026
Dividend Yield
1.81%
N/A
EPS Growth
32.43
N/A
EPS
0.31
N/A
Revenue
$389,830,000.00
$2,000,000.00
Revenue This Year
$15.53
N/A
Revenue Next Year
$3.83
N/A
P/E Ratio
$49.55
N/A
Revenue Growth
10.26
N/A
52 Week Low
$14.06
$4.50
52 Week High
$34.82
$11.41

Technical Indicators

Market Signals
Indicator
EVI
SGMT
Relative Strength Index (RSI) 43.66 52.37
Support Level $14.06 $7.09
Resistance Level $21.36 $7.39
Average True Range (ATR) 0.92 0.43
MACD 0.14 0.04
Stochastic Oscillator 43.90 52.14

Price Performance

Historical Comparison
EVI
SGMT

About EVI EVI Industries Inc.

EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: